Skip to main content

Research Repository

Advanced Search

All Outputs (4)

Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets (2020)
Journal Article
Kurozumi, S., Alsaleem, M., Monteiro, C. J., Bhardwaj, K., Joosten, S. E., Fujii, T., …Johnston, S. J. (2020). Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets. Breast Cancer Research, 22, Article 85. https://doi.org/10.1186/s13058-020-01324-4

© 2020 The Author(s). Background: Invasive lobular carcinoma (ILC) accounts for 10-15% of primary breast cancers and is typically estrogen receptor alpha positive (ER+) and ERBB2 non-amplified. Somatic mutations in ERBB2/3 are emerging as a tractable... Read More about Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.

Molecular Complexity of Lymphovascular Invasion: The Role of Cell Migration in Breast Cancer as a Prototype (2020)
Journal Article
Kariri, Y. A., Aleskandarany, M. A., Joseph, C., Toss, M. S., Kurozumi, S., Mohammed, O. J., …Rakha, E. A. (2020). Molecular Complexity of Lymphovascular Invasion: The Role of Cell Migration in Breast Cancer as a Prototype. Pathobiology, 87, 218–231. https://doi.org/10.1159/000508337

Lymphovascular invasion (LVI) is associated with poor outcome in breast cancer (BC); however, its underlying mechanisms remain ill-defined. LVI in BC develops through complex molecular pathways involving not only the interplay with the surrounding mi... Read More about Molecular Complexity of Lymphovascular Invasion: The Role of Cell Migration in Breast Cancer as a Prototype.

Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival (2020)
Journal Article
Joseph, C., Alsaleem, M., Orah, N., Narasimha, P. L., Miligy, I. M., Kurozumi, S., …Rakha, E. A. (2020). Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival. Breast Cancer Research and Treatment, 182, 267–282. https://doi.org/10.1007/s10549-020-05670-x

Purpose: MMP9 is a matricellular protein associated with extracellular matrix (ECM) remodelling, that promotes tumour progression, and modulates the activity of cell adhesion molecules and cytokines. This study aims to assess the prognostic value of... Read More about Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival.

Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer (2020)
Journal Article
Aljohani, A. I., Joseph, C., Kurozumi, S., Mohammed, O. J., Miligy, I. M., Green, A. R., & Rakha, E. (2020). Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer. Breast Cancer Research and Treatment, 181(3), 541-551. https://doi.org/10.1007/s10549-020-05646-x

Background: Breast cancer (BC) is a disease with variable morphology, clinical behaviour and response to therapy. Identifying factors associated with the progression of early stage BC can help understand the risk of metastasis and guide treatment dec... Read More about Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer.